about
Quetiapine versus other atypical antipsychotics for schizophreniaAntipsychotic drug treatment for elderly people with late-onset schizophreniaZiprasidone versus other atypical antipsychotics for schizophreniaWhat can triumphs and tribulations from drug research in Alzheimer's disease tell us about the development of psychotropic drugs in general?Selective activation of M4 muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairments and enhances associative learning in rodents.Antipsychotic drug-like effects of the selective M4 muscarinic acetylcholine receptor positive allosteric modulator VU0152100Neurodevelopmental animal models of schizophrenia: role in novel drug discovery and developmentN-aryl piperazine metabotropic glutamate receptor 5 positive allosteric modulators possess efficacy in preclinical models of NMDA hypofunction and cognitive enhancement.Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophreniaMedication adherence and utilization in patients with schizophrenia or bipolar disorder receiving aripiprazole, quetiapine, or ziprasidone at hospital discharge: a retrospective cohort study.Paliperidone extended-release: does it have a place in antipsychotic therapy?Medication preferences and adherence among individuals with severe mental illness and psychiatric advance directivesLost in translation: neuropsychiatric drug development.Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making.The relationship between suicide and violence in schizophrenia: analysis of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) dataset.Where to position clozapine: re-examining the evidence.How have developments in molecular imaging techniques furthered schizophrenia research?Overview of glutamatergic neurotransmission in the nervous system.Palliative models of care for later stages of mental disorder: maximizing recovery, maintaining hope, and building morale.Clinical factors related to schizophrenia relapse.The effects of cognitive therapy on hallucinations in patients with schizophrenia.Neuregulin-2 ablation results in dopamine dysregulation and severe behavioral phenotypes relevant to psychiatric disorders.Gabapentin adjunctive to risperidone or olanzapine in partially responsive schizophrenia: an open-label pilot study.Reboxetine enhances the olanzapine-induced antipsychotic-like effect, cortical dopamine outflow and NMDA receptor-mediated transmission.Severe weight gain with long-acting injectable risperidone: a case report.Clozapine-associated weight loss.Dopamine, psychosis and schizophrenia: the widening gap between basic and clinical neuroscience.Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review.Effect of time and duration of untreated psychosis on cognitive and social functioning in Chinese patients with first-episode schizophrenia: A 1-year study.
P2860
Q24202427-2B358470-85BD-4D1F-AE76-C5AA5903218FQ24203649-0C9C8130-7AF1-4914-9D75-86A5B17E130AQ24240260-0691B58D-C39F-41FC-B7B8-B6A84CD24E40Q28083481-969AB31B-D67D-4863-BC42-3DADCA08012AQ30406145-F8F591D7-EF36-4729-A2C9-06B26990D602Q30410518-42C78D00-9B52-483B-B4CC-09B90D78B5E8Q30414108-636EA9C1-3F13-4664-8915-D9414629A203Q30427199-3857BDA1-2523-4FB8-9113-172F6DD4922BQ30459624-B0C73F42-042E-4402-AC80-BDA02EDFF908Q34362623-CFC492F7-C634-4006-86A1-E4FAA1F67669Q34712339-115D6248-DB35-41C8-A216-59E2BF2088B3Q36913938-0592E898-5834-4F09-AF1E-A3B6D551C0D6Q37527193-32A3710E-17BB-4FEF-9942-9AE357D93BA9Q37532575-B187A1CC-4766-4C7E-9B31-051D6D942FAFQ37706450-49A00E13-4CD7-41D4-BE42-2D8F1885B453Q37801988-94FA059B-8AF2-48A4-8F94-8FAE364A425EQ37829639-DD0DE573-4337-4D28-B203-4B144CCC9868Q37926162-EFF60D26-2E4B-4CE8-B7A4-A173A3C4F77FQ37981965-60BF8634-36BD-4266-9B9B-05C84929BC65Q38799868-09E61F6B-4314-482F-AA89-5434FAE4BECBQ41026083-BA98FB30-4130-4D4B-A9B2-07FDB9918F7DQ41700939-E1E9A0BB-948F-44C5-B7C7-C817AB5D7EF4Q41732419-EC091974-9EFF-44C6-A174-6C562DA32C9EQ41833495-6A9FF395-61B7-4790-B530-F225310689C3Q42359424-78A2D2EB-3090-4FCA-96A7-168DA8B866FEQ46098816-A402ACB9-C4B3-4229-B5ED-28F3C711BECAQ47550545-6D3CE6BA-8895-4294-B65E-A1F158C520E0Q47552120-5549B3E3-D34C-42E2-A402-DD1CE9CC2030Q50598149-F8DD362F-3BA9-424F-987E-B7DD2E92A7B3
P2860
description
2008 nî lūn-bûn
@nan
2008 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
What CATIE found: results from the schizophrenia trial.
@en
What CATIE found: results from the schizophrenia trial.
@nl
type
label
What CATIE found: results from the schizophrenia trial.
@en
What CATIE found: results from the schizophrenia trial.
@nl
prefLabel
What CATIE found: results from the schizophrenia trial.
@en
What CATIE found: results from the schizophrenia trial.
@nl
P2093
P2860
P356
P1433
P1476
What CATIE found: results from the schizophrenia trial.
@en
P2093
Jeffrey A Lieberman
John K Hsiao
Joseph P McEvoy
Marvin S Swartz
Richard S E Keefe
Sonia M Davis
T Scott Stroup
P2860
P304
P356
10.1176/PS.2008.59.5.500
P577
2008-05-01T00:00:00Z